Dermorphin is a naturally occurring hepta-peptide originally isolated from amphibian skin, now widely utilised in laboratory settings to study mu-opioid receptor binding affinities. Through rigorous peptide synthesis, this compound is generated for precise cellular assays, allowing researchers to observe robust receptor activation and subsequent intracellular signalling cascades. When examining its molecular stability, scientists note that the inclusion of a D-amino acid at the second position protects the peptide from rapid enzymatic degradation. Due to its status as a premium research chemical, UK laboratories utilise this peptide to map out complex receptor interactions without the confounding variables often seen in less stable analogues. Proper reconstitution protocols are essential to maintain the structural integrity of the lyophilised solid before introducing it to cell cultures. In an in vitro analysis of receptor kinetics, Dermorphin demonstrates profound selectivity, triggering the inhibition of adenylate cyclase and a measurable decrease in cyclic AMP production. Further structural data and receptor binding metrics can be verified via PubChem, confirming its status as a highly specific tool for molecular biology research.
Research trends often mention the phrase "stronger than morphine" in public search data when exploring this compound. Current literature on this reagent is centred on cellular and molecular laboratory models, specifically investigating receptor binding affinities. Amino Peptides does not supply this compound for any bodily protocol. Strictly for laboratory research.
- Exhibits profound selectivity and high-affinity binding to the mu-opioid receptor (MOR) in isolated cell membrane preparations.
- Demonstrates negligible interaction with delta-opioid (DOR) and kappa-opioid (KOR) receptors in competitive radioligand binding experiments.
- Interacts with G-protein coupled receptor (GPCR) domains, specifically stabilising the active conformation of the mu-opioid receptor in cell-free systems.
- Initiates robust G-protein activation, measured by [35S]GTPgammaS binding in transfected cellular models.
- Triggers the inhibition of adenylyl cyclase activity, leading to a marked reduction in intracellular cyclic AMP (cAMP) accumulation in lab experiments.
- Promotes the recruitment of beta-arrestin to the mu-opioid receptor, facilitating receptor internalisation pathways in cultured cellular environments.
- Modulates intracellular calcium flux and potassium channel conductance through G-protein beta-gamma subunit signalling cascades in isolated cell lines.
Technical Specifications
Variant Breakdown
- 2mg Vial: Ideal for initial laboratory evaluation-response assays and short-term receptor binding studies, providing precise quantities for small-scale laboratory stock preparation.
- 10mg Vial: Optimised for high-throughput screening and extended cell culture experiments, ensuring a consistent supply of the peptide for comprehensive molecular profiling.
Quality Assurance
- HPLC Verification: High-performance liquid chromatography ensures the peptide achieves greater than 99 percent purity, eliminating unwanted synthesis by-products.
- Mass Spectrometry: Advanced mass analysis confirms the exact molecular weight of 802.9 g/mol, verifying the structural identity of the lyophilised peptide.
- Lyophilised Form: The compound is supplied as a freeze-dried solid to maximise shelf life and preserve the delicate amino acid sequence prior to laboratory use.
- Laboratory Characterisation: Each batch undergoes rigorous physical and chemical testing to ensure it meets strict analytical research grade standards.
Research Mechanism
- Receptor Binding: Dermorphin selectively binds to the mu-opioid receptor (MOR) on the cell membrane with exceptionally high affinity, acting as a potent agonist in cellular models.
- Enzyme Inhibition: Upon receptor activation, the peptide triggers the G-protein coupled cascade, leading to the direct inhibition of the adenylate cyclase enzyme.
- Secondary Messenger Reduction: The inhibition of adenylate cyclase results in a sharp decrease in intracellular cyclic AMP (cAMP) levels, altering downstream cellular signalling.
- Ion Channel Modulation: The signalling cascade promotes the opening of potassium channels and the closing of voltage-gated calcium channels, resulting in cellular hyperpolarisation.
- Enzymatic Resistance: The presence of a D-alanine residue at position two provides significant resistance to aminopeptidases, ensuring prolonged activity during in vitro assays.
Reconstitution & Storage Data
| Vial Strength | Solvent Added | Resulting Concentration |
| 2mg | 1 mL Bacteriostatic Reconstitution Solution | 2.00 mg/mL |
| 2mg | 2 mL Bacteriostatic Reconstitution Solution | 1.00 mg/mL |
| 10mg | 1 mL Bacteriostatic Reconstitution Solution | 10.00 mg/mL |
| 10mg | 2 mL Bacteriostatic Reconstitution Solution | 5.00 mg/mL |
- Lyophilised (Powder): Store in a standard refrigerator (2-8°C) for up to 3 months. For long-term preservation, freeze at -20°C.
- Reconstituted (Liquid): Store at 2-8°C (Refrigerated).
Scientific References
Peptides: "Dermorphin: a new paradigm in mu-opioid receptor research" View Study
European Journal of Pharmacology: "Receptor binding profiles of dermorphin and its analogues" View Study
Journal of Biological Chemistry: "Structural determinants of dermorphin interaction with the mu-opioid receptor" View Study
Neuropharmacology: "In vitro characterisation of amphibian-derived opioid peptides" View Study
Molecular Pharmacology: "G-protein activation by dermorphin in isolated cell membranes" View Study
